172 related articles for article (PubMed ID: 29997888)
1. Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy.
Köther J; Mandl A; Allekotte S; Astvatsatourov A; Chwieralski J; Liedtke JP; Pieper-Fürst U; Raskopf E; Shah-Hosseini K; Mösges R
Clin Transl Allergy; 2018; 8():28. PubMed ID: 29997888
[TBL] [Abstract][Full Text] [Related]
2. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
3. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L
Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
[TBL] [Abstract][Full Text] [Related]
5. Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season.
Nolte H; Waserman S; Ellis AK; Biedermann T; Würtzen PA
J Allergy Clin Immunol Pract; 2021 May; 9(5):1871-1878. PubMed ID: 33548518
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
[TBL] [Abstract][Full Text] [Related]
7. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.
Mösges R; Bachert C; Panzner P; Calderon MA; Haazen L; Pirotton S; Wathelet N; Durham SR; Bonny MA; Legon T; von Frenckell R; Pfaar O; Shamji MH
Allergy; 2018 Sep; 73(9):1842-1850. PubMed ID: 29512827
[TBL] [Abstract][Full Text] [Related]
8. Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.
Nelson HS; Bernstein DI; Biedermann T; Nolte H
Allergy Asthma Proc; 2024 Jan; 45(1):33-36. PubMed ID: 38151733
[No Abstract] [Full Text] [Related]
9. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
10. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial.
Biedermann T; Kuna P; Panzner P; Valovirta E; Andersson M; de Blay F; Thrane D; Jacobsen SH; Stage BS; Winther L
J Allergy Clin Immunol; 2019 Mar; 143(3):1058-1066.e6. PubMed ID: 30654054
[TBL] [Abstract][Full Text] [Related]
11. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
Mösges R; Ritter B; Kayoko G; Allekotte S
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
[TBL] [Abstract][Full Text] [Related]
12. Optimum treatment strategies for polyallergic patients - analysis of a large observational trial.
Shah-Hosseini K; Mioc K; Hadler M; Karagiannis E; Mösges R
Curr Med Res Opin; 2015 Dec; 31(12):2249-59. PubMed ID: 26366617
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children.
Hébert J; Blaiss M; Waserman S; Kim H; Creticos P; Maloney J; Kaur A; Li Z; Nelson H; Nolte H
Allergy Asthma Clin Immunol; 2014; 10(1):53. PubMed ID: 25685162
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis.
Ellis AK; Gagnon R; Bernstein DI; Nolte H
Allergy Asthma Clin Immunol; 2021 Dec; 17(1):127. PubMed ID: 34886880
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis.
Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
JAMA Intern Med; 2015 Aug; 175(8):1301-9. PubMed ID: 26120825
[TBL] [Abstract][Full Text] [Related]
17. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study.
de Blay F; Barnig C; Kanny G; Purohit A; Leynadier F; Tunon de Lara JM; Chabane H; Guérin L;
Ann Allergy Asthma Immunol; 2007 Nov; 99(5):453-61. PubMed ID: 18051216
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis.
Malling HJ; Montagut A; Melac M; Patriarca G; Panzner P; Seberova E; Didier A
Clin Exp Allergy; 2009 Mar; 39(3):387-93. PubMed ID: 19134019
[TBL] [Abstract][Full Text] [Related]
19. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.
Wahn U; Klimek L; Ploszczuk A; Adelt T; Sandner B; Trebas-Pietras E; Eberle P; Bufe A;
J Allergy Clin Immunol; 2012 Oct; 130(4):886-93.e5. PubMed ID: 22939758
[TBL] [Abstract][Full Text] [Related]
20. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
